When does iX Biopharma report earnings and why does it matter for 42C.SI stock?

Earnings are scheduled for 06 Feb 2026. The report matters because revenue beats, guidance changes or clinical updates can move 42C.SI stock sharply given thin liquidity and active development programs.

What are the biggest financial risks shown in the 42C.SI analysis?

Major risks are negative EPS (**-0.01**), low current ratio (**0.47**), and high price to book (**412.98**). These point to cash burn and valuation mismatch ahead of earnings.

How does technical momentum affect trading around the 42C.SI earnings?

Technicals look overbought with RSI **80.23** and CCI **151.70**. That increases the chance of a quick pullback if earnings disappoint, so intraday traders should use stop limits.

What does Meyka AI's forecast imply for 42C.SI stock performance?

Meyka AI's model projects monthly **S$0.25** and yearly **S$0.85**, implying potential upside. These are model-based projections and not guarantees; results depend on earnings, cash flow and clinical progress.

SG Stocks

05 Feb 2026 Earnings: iX Biopharma (42C.SI, SES) S$0.17 ahead of report

ByHuzaifa Zahoor February 5, 2026

iX Biopharma (42C.SI) trades at S$0.17 on the Singapore Exchange (SES) as markets watch an earnings announcement due 06 Feb 2026. The upcoming report is the immediate catalyst for intraday flows and liquidity, with 6,303,600 shares trading today and a 50-day average of 0.15. We focus on how short-term technicals, cash flow metrics and clinical-development milestones could move 42C.SI stock into earnings week